Evommune (NYSE:EVMN) Insider Sells $452,600.00 in Stock

Evommune, Inc. (NYSE:EVMN) insider Janice Suzann Drew sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $22.63, for a total transaction of $452,600.00. Following the sale, the insider owned 67,794 shares in the company, valued at $1,534,178.22. The trade was a 22.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Evommune Price Performance

Shares of EVMN stock opened at $24.93 on Friday. The company’s fifty day simple moving average is $22.98 and its two-hundred day simple moving average is $22.31. Evommune, Inc. has a 1 year low of $13.89 and a 1 year high of $33.20. The stock has a market capitalization of $898.16 million and a price-to-earnings ratio of -2.62.

Evommune (NYSE:EVMN) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.64) EPS for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.19. Equities research analysts anticipate that Evommune, Inc. will post -2.85 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have weighed in on the company. Morgan Stanley lifted their target price on Evommune from $54.00 to $55.00 and gave the company an “overweight” rating in a report on Monday, May 11th. Oppenheimer assumed coverage on shares of Evommune in a report on Tuesday, April 7th. They issued an “outperform” rating and a $50.00 price target on the stock. Clear Str upgraded shares of Evommune to a “strong-buy” rating in a research report on Tuesday, March 17th. Stifel Nicolaus initiated coverage on shares of Evommune in a research note on Friday, May 1st. They set a “buy” rating and a $54.00 price objective for the company. Finally, Wall Street Zen lowered shares of Evommune from a “hold” rating to a “sell” rating in a report on Saturday, June 13th. Three investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $49.25.

Institutional Investors Weigh In On Evommune

Several large investors have recently added to or reduced their stakes in EVMN. China Universal Asset Management Co. Ltd. bought a new position in Evommune in the 4th quarter worth about $34,000. Strs Ohio bought a new stake in shares of Evommune during the 1st quarter valued at about $41,000. The Manufacturers Life Insurance Company bought a new stake in shares of Evommune during the 4th quarter valued at about $179,000. XTX Topco Ltd purchased a new position in shares of Evommune during the fourth quarter worth about $321,000. Finally, Oxford Asset Management LLP purchased a new position in shares of Evommune during the fourth quarter worth about $335,000.

About Evommune

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.